1. BanicM, MalfertheinerP, BabicZ, et al.Historical impact to drive research in peptic ulcer disease. Dig Dis2011;29:444. CrossRef

2. ChanHL, WuJC, ChanFK, et al.Is non‐Helicobacter pylori, non‐NSAID peptic ulcer a common cause of upper GI bleeding? A prospective study of 977 patients. Gastrointest Endosc2001;53:438. CrossRef

3. ChowDK, SungJJ. Non‐NSAID non‐H. pylori ulcer disease. Best Pract Res Clin Gastroenterol2009;23:3. CrossRef

4. HuangSC, SheuBS, LeeSC, et al.Etiology and treatment of childhood peptic ulcer disease in Taiwan: a single center 9‐year experience. J Formos Med Assoc2010;109:75. CrossRef

5. MusumbaC, JorgensenA, SuttonL, et al.The relative contribution of NSAIDs and Helicobacter pylori to the aetiology of endoscopically‐diagnosed peptic ulcer disease: observations from a tertiary referral hospital in the UK between 2005 and 2010. Aliment Pharmacol Ther2012;36:48. CrossRef

6. NishikawaK, SugiyamaT, KatoM, et al.Non‐Helicobacter pylori and non‐NSAID peptic ulcer disease in the Japanese population. Eur J Gastroenterol Hepatol2000;12:635. CrossRef

7. XiaHH, WongBC, WongKW, et al.Clinical and endoscopic characteristics of non‐Helicobacter pylori, non‐NSAID duodenal ulcers: a long‐term prospective study. Aliment Pharmacol Ther2001;15:1875. CrossRef

8. YakoobJ, JafriW, JafriN, et al.Prevalence of non‐Helicobacter pylori duodenal ulcer in Karachi, Pakistan. World J Gastroenterol2005;11:3562. CrossRef

9. SonnenbergA, EverhartJE. Health impact of peptic ulcer in the United States. Am J Gastroenterol1997;92:614.

10. MarshallBJ, WarrenJR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet1984;1:1311. CrossRef

11. O'RourkeJL, GrehanM, LeeA. Non‐pylori Helicobacter species in humans. Gut2001;49:601. CrossRef

12. KustersJG, KuipersEJ. Non‐pylori Helicobacter infections in humans. Eur J Gastroenterol Hepatol1998;10:239. CrossRef

13. ArchimandritisA, MarkoulatosP, TjivrasM, et al.Herpes simplex virus types 1 and 2 and cytomegalovirus in peptic ulcer disease and non‐ulcer dyspepsia. Hepatogastroenterology1992;39:540.

14. LohrJM, NelsonJA, OldstoneMB. Is herpes simplex virus associated with peptic ulcer disease?J Virol1990;64:2168.

15. TsamakidisK, PanotopoulouE, DimitroulopoulosD, et al.Herpes simplex virus type 1 in peptic ulcer disease: an inverse association with Helicobacter pylori. World J Gastroenterol2005;11:6644. CrossRef

16. ChiuHM, WuMS, HungCC, et al.Low prevalence of Helicobacter pylori but high prevalence of cytomegalovirus‐associated peptic ulcer disease in AIDS patients: Comparative study of symptomatic subjects evaluated by endoscopy and CD4 counts. J Gastroenterol Hepatol2004;19:423. CrossRef

17. HimotoT, GodaF, OkuyamaH, et al.Cytomegalovirus‐associated acute gastric mucosal lesion in an immunocompetent host. Intern Med2009;48:1521. CrossRef

18. MoriH, FujiharaS, NishiyamaN, et al.Cytomegalovirus‐associated gastric ulcer: a side effect of steroid injections for pyloric stenosis. World J Gastroenterol2013;19:1143. CrossRef

19. ShuklaSK, PrasadKN, TripathiA, et al.Expression profile of latent and lytic transcripts of epstein‐barr virus in patients with gastroduodenal diseases: a study from northern India. J Med Virol2012;84:1289. CrossRef

20. SaxenaA, Nath PrasadK, Chand GhoshalU, et al.Association of Helicobacter pylori and Epstein‐Barr virus with gastric cancer and peptic ulcer disease. Scand J Gastroenterol2008;43:669. CrossRef

21. RahmeE, BarkunA, NedjarH, et al.Hospitalizations for upper and lower GI events associated with traditional NSAIDs and acetaminophen among the elderly in Quebec, Canada. Am J Gastroenterol2008;103:872. CrossRef

22. DohertyM, HawkeyC, GoulderM, et al.A randomised controlled trial of ibuprofen, paracetamol or a combination tablet of ibuprofen/paracetamol in community‐derived people with knee pain. Ann Rheum Dis2011;70:1534. CrossRef

23. KefalasCH. Gastroduodenal Crohn's disease. Proc (Bayl Univ Med Cent)2003;16:147.

24. MottetC, JuilleratP, PittetV, et al.Upper gastrointestinal Crohn's disease. Digestion2007;76:136. CrossRef

25. IngleSB, Hinge IngleCR. Eosinophilic gastroenteritis: an unusual type of gastroenteritis. World J Gastroenterol2013;19:5061. CrossRef

26. AthertonJC, BlaserMJ. Coadaptation of Helicobacter pylori and humans: ancient history, modern implications. J Clin Invest2009;119:2475. CrossRef

27. SonnenbergA. Birth cohort patterns of gastric cancer and peptic ulcer among non‐whites in the USA. J Epidemiol Community Health2011;65:1059. CrossRef

28. KurataJH, HaileBM. Epidemiology of peptic ulcer disease. Clin Gastroenterol1984;13:289.

29. SungJJ, KuipersEJ, El‐SeragHB. Systematic review: the global incidence and prevalence of peptic ulcer disease. Aliment Pharmacol Ther2009;29:938. CrossRef

30. KuipersEJ, ThijsJC, FestenHP. The prevalence of Helicobacter pylori in peptic ulcer disease. Aliment Pharmacol Ther1995;9(Suppl 2):59.

31. AroP, StorskrubbT, RonkainenJ, et al.Peptic ulcer disease in a general adult population: the Kalixanda study: a random population‐based study. Am J Epidemiol2006;163:1025. CrossRef

32. ZagariRM, LawGR, FuccioL, et al.Dyspeptic symptoms and endoscopic findings in the community: the Loiano‐Monghidoro study. Am J Gastroenterol2010;105:565. CrossRef

33. LiZ, ZouD, MaX, et al.Epidemiology of peptic ulcer disease: endoscopic results of the systematic investigation of gastrointestinal disease in China. Am J Gastroenterol2010;105:2570. CrossRef

34. ChibaT, SenoH, MarusawaH, et al.Host factors are important in determining clinical outcomes of Helicobacter pylori infection. J Gastroenterol2006;41:1. CrossRef

35. WongBC, ChingCK, LamSK, et al.Differential north to south gastric cancer‐duodenal ulcer gradient in China. China Ulcer Study Group. J Gastroenterol Hepatol1998;13:1050. CrossRef

36. WangFW, TuMS, MarGY, et al.Prevalence and risk factors of asymptomatic peptic ulcer disease in Taiwan. World J Gastroenterol2011;17:1199. CrossRef

37. DuttaAK, ChackoA, BalekuduruA, et al.Time trends in epidemiology of peptic ulcer disease in India over two decades. Indian J Gastroenterol2012;31:111. CrossRef

38. ToveyFI, HobsleyM, KaushikSP, et al.Duodenal gastric metaplasia and Helicobacter pylori infection in high and low duodenal ulcer‐prevalent areas in India. J Gastroenterol Hepatol2004;19:497. CrossRef

39. KangJY, YeohKG, HoKY, et al.Racial differences in Helicobacter pylori seroprevalence in Singapore: correlation with differences in peptic ulcer frequency. J Gastroenterol Hepatol1997;12:655. CrossRef

40. KiddM, LouwJA, MarksIN. Helicobacter pylori in Africa: observations on an “enigma within an enigma”. J Gastroenterol Hepatol1999;14:851. CrossRef

41. AghaA, GrahamDY. Evidence‐based examination of the African enigma in relation to Helicobacter pylori infection. Scand J Gastroenterol2005;40:523. CrossRef

42. BardhanKD, WilliamsonM, RoystonC, et al.Admission rates for peptic ulcer in the trent region, UK, 1972–2000. changing pattern, a changing disease?Dig Liver Dis2004;36:577. CrossRef

43. PrimatestaP, GoldacreMJ, SeagroattV. Changing patterns in the epidemiology and hospital care of peptic ulcer. Int J Epidemiol1994;23:1206. CrossRef

44. HighamJ, KangJY, MajeedA. Recent trends in admissions and mortality due to peptic ulcer in England: increasing frequency of haemorrhage among older subjects. Gut2002;50:460. CrossRef

45. KangJY, EldersA, MajeedA, et al.Recent trends in hospital admissions and mortality rates for peptic ulcer in Scotland 1982‐2002. Aliment Pharmacol Ther2006;24:65. CrossRef

46. LassenA, HallasJ, Schaffalitzky de MuckadellOB. Complicated and uncomplicated peptic ulcers in a Danish county 1993‐2002: a population‐based cohort study. Am J Gastroenterol2006;101:945. CrossRef

47. PostPN, KuipersEJ, MeijerGA. Declining incidence of peptic ulcer but not of its complications: a nation‐wide study in The Netherlands. Aliment Pharmacol Ther2006;23:1587. CrossRef

48. ManuelD, CutlerA, GoldsteinJ, et al.Decreasing prevalence combined with increasing eradication of Helicobacter pylori infection in the United States has not resulted in fewer hospital admissions for peptic ulcer disease‐related complications. Aliment Pharmacol Ther2007;25:1423. CrossRef

49. WangYR, RichterJE, DempseyDT. Trends and outcomes of hospitalizations for peptic ulcer disease in the United States, 1993 to 2006. Ann Surg2010;251:51. CrossRef

50. SadicJ, BorgstromA, ManjerJ, et al.Bleeding peptic ulcer – time trends in incidence, treatment and mortality in Sweden. Aliment Pharmacol Ther2009;30:392. CrossRef

51. PounderRE, NgD. The prevalence of Helicobacter pylori infection in different countries. Aliment Pharmacol Ther1995;9(Suppl 2):33.

52. AsakaM, KimuraT, KudoM, et al.Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population. Gastroenterology1992;102:760.

53. WebbPM, KnightT, GreavesS, et al.Relation between infection with Helicobacter pylori and living conditions in childhood: evidence for person to person transmission in early life. BMJ1994;308:750. CrossRef

54. Uvnas‐MobergK, BruzeliusG, AlsterP, et al.Oxytocin increases and a specific oxytocin antagonist decreases pain threshold in male rats. Acta Physiol Scand1992;144:487. CrossRef

55. AnandBS, RaedAK, MalatyHM, et al.Low point prevalence of peptic ulcer in normal individuals with Helicobacter pylori infection. Am J Gastroenterol1996;91:1112.

56. SipponenP, VarisK, FrakiO, et al.Cumulative 10‐year risk of symptomatic duodenal and gastric ulcer in patients with or without chronic gastritis. A clinical follow‐up study of 454 outpatients. Scand J Gastroenterol1990;25:966. CrossRef

57. HuntRH, XiaoSD, MegraudF, et al.; for the World Gastroenterology Organisation. WGO Global Guideline: Helicobacter pylori in developing countries. J Clin Gastroenterol2011;45:383. CrossRef

58. AmentPW, ChildersRS. Prophylaxis and treatment of NSAID‐induced gastropathy. Am Fam Physician1997;55:1323, 31‐2.

59. SoniA. Aspirin use among the adult US noninstitutionalized population, with and without indicators of heart disease [online]. 2007, Statistical Brief #179. Rockville, MD: Agency for Healthcare Research and Quality. Available at: <http://www.meps.ahrq.gov/mepsweb/data_files/publications/st179/stat179.shtml>.

60. ElliottSL, YeomansND, BuchananRR, et al.Efficacy of 12 months' misoprostol as prophylaxis against NSAID‐induced gastric ulcers. A placebo‐controlled trial. Scand J Rheumatol1994;23:171. CrossRef

61. HartJ, HawkeyCJ, LanasA, et al.Predictors of gastroduodenal erosions in patients taking low‐dose aspirin. Aliment Pharmacol Ther2010;31:143. CrossRef

62. BombardierC, LaineL, ReicinA, et al.Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med2000;343:1520, 2 p following 8. CrossRef

63. RaskinJB. Gastrointestinal effects of nonsteroidal anti‐inflammatory therapy. Am J Med1999;106(5B):3S. CrossRef

64. FriesJF, WilliamsCA, BlochDA, et al.Nonsteroidal anti‐inflammatory drug‐associated gastropathy: incidence and risk factor models. Am J Med1991;91:213. CrossRef

65. BhattDL, ScheimanJ, AbrahamNS, et al.ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol2008;52:1502. CrossRef

66. FriesJF, MurtaghKN, BennettM, et al.The rise and decline of nonsteroidal antiinflammatory drug‐associated gastropathy in rheumatoid arthritis. Arthritis Rheum2004;50:2433. CrossRef

67. GriffinMR, PiperJM, DaughertyJR, et al.Nonsteroidal anti‐inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med1991;114:257. CrossRef

68. PapatheodoridisGV, SougioultzisS, ArchimandritisAJ. Effects of Helicobacter pylori and nonsteroidal anti‐inflammatory drugs on peptic ulcer disease: a systematic review. Clin Gastroenterol Hepatol2006;4:130. CrossRef

69. LanzaFL. A guideline for the treatment and prevention of NSAID‐induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol1998;93:2037. CrossRef

70. HungLC, ChingJY, SungJJ, et al.Long‐term outcome of Helicobacter pylori‐negative idiopathic bleeding ulcers: a prospective cohort study. Gastroenterology2005;128:1845. CrossRef

71. JangHJ, ChoiMH, ShinWG, et al.Has peptic ulcer disease changed during the past ten years in Korea? A prospective multi‐center study. Dig Dis Sci2008;53:1527. CrossRef

72. GisbertJP, BlancoM, MateosJM, et al.H. pylori‐negative duodenal ulcer prevalence and causes in 774 patients. Dig Dis Sci1999;44:2295. CrossRef

73. ArroyoMT, ForneM, de ArgilaCM, et al.The prevalence of peptic ulcer not related to Helicobacter pylori or non‐steroidal anti‐inflammatory drug use is negligible in southern Europe. Helicobacter2004;9:249. CrossRef

74. JyotheeswaranS, ShahAN, JinHO, et al.Prevalence of Helicobacter pylori in peptic ulcer patients in greater Rochester, NY: is empirical triple therapy justified?Am J Gastroenterol1998;93:574. CrossRef

75. CiociolaAA, McSorleyDJ, TurnerK, et al.Helicobacter pylori infection rates in duodenal ulcer patients in the United States may be lower than previously estimated. Am J Gastroenterol1999;94:1834. CrossRef

76. TsujiH, KohliY, FukumitsuS, et al.Helicobacter pylori‐negative gastric and duodenal ulcers. J Gastroenterol1999;34:455. CrossRef

77. AoyamaN, ShinodaY, MatsushimaY, et al.Helicobacter pylori‐negative peptic ulcer in Japan: which contributes most to peptic ulcer development, Helicobacter pylori, NSAIDS or stress?J Gastroenterol2000;35(Suppl 12):33.

78. NivY, BoltinD. Secreted and membrane‐bound mucins and idiopathic peptic ulcer disease. Digestion2012;86:258. CrossRef

79. McCollKE. How I manage H. pylori‐negative, NSAID/aspirin‐negative peptic ulcers. Am J Gastroenterol2009;104:190. CrossRef

80. ChivertonSG, HuntRH. Smoking and duodenal ulcer disease. J Clin Gastroenterol1989;11(Suppl 1):S29. CrossRef

81. StemmermannGN, MarcusEB, BuistAS, et al.Relative impact of smoking and reduced pulmonary function on peptic ulcer risk. A prospective study of Japanese men in Hawaii. Gastroenterology1989;96:1419.

82. McCarthyDM. Smoking and ulcers – time to quit. N Engl J Med1984;311:726. CrossRef

83. RosenstockS, JorgensenT, BonnevieO, et al.Risk factors for peptic ulcer disease: a population based prospective cohort study comprising 2416 Danish adults. Gut2003;52:186. CrossRef

84. BorodyTJ, GeorgeLL, BrandlS, et al.Smoking does not contribute to duodenal ulcer relapse after Helicobacter pylori eradication. Am J Gastroenterol1992;87:1390.

85. BardhanKD, GrahamDY, HuntRH, et al.Effects of smoking on cure of Helicobacter pylori infection and duodenal ulcer recurrence in patients treated with clarithromycin and omeprazole. Helicobacter1997;2:27. CrossRef

86. ChanFK, SungJJ, LeeYT, et al.Does smoking predispose to peptic ulcer relapse after eradication of Helicobacter pylori?Am J Gastroenterol1997;92:442.

87. TahaAS, AngersonWJ, PrasadR, et al.Upper gastrointestinal bleeding and the changing use of COX‐2 non‐steroidal anti‐inflammatory drugs and low‐dose aspirin. Aliment Pharmacol Ther2007;26:1171. CrossRef

88. AldooriWH, GiovannucciEL, StampferMJ, et al.A prospective study of alcohol, smoking, caffeine, and the risk of duodenal ulcer in men. Epidemiology1997;8:420. CrossRef

89. ArmstrongD, ArnoldR, ClassenM, et al.RUDER – a prospective, two‐year, multicenter study of risk factors for duodenal ulcer relapse during maintenance therapy with ranitidine. Dig Dis Sci1994;39:1425. CrossRef

90. ReynoldsJC. Famotidine therapy for active duodenal ulcers. A multivariate analysis of factors affecting early healing. Ann Intern Med1989;111:7. CrossRef

91. BattagliaB, Di MarioF, DottoP, et al.Alcohol intake and acute duodenal ulcer healing. Am J Gastroenterol1990;85:1198.

92. SonnenbergA, Muller‐LissnerSA, VogelE, et al.Predictors of duodenal ulcer healing and relapse. Gastroenterology1981;81:1061.

93. KangJY, YeohKG, ChiaHP, et al.Chili – protective factor against peptic ulcer?Dig Dis Sci1995;40:576. CrossRef

94. PiperJM, RayWA, DaughertyJR, et al.Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti‐inflammatory drugs. Ann Intern Med1991;114:735. CrossRef

95. LevensteinS. The very model of a modern etiology: a biopsychosocial view of peptic ulcer. Psychosom Med2000;62:176. CrossRef

96. RobinsonSC, BrucerM. The body build of the male ulcer patient. Am J Dig Dis1940;7:365. CrossRef

97. SpicerCC, StewartDN, DeDM, et al.Perforated peptic ulcer during the period of heavy air‐raids. Lancet1942;243:14. CrossRef

98. AoyamaN, KinoshitaY, FujimotoS, et al.Peptic ulcers after the Hanshin‐Awaji earthquake: increased incidence of bleeding gastric ulcers. Am J Gastroenterol1998;93:311. CrossRef

99. OvermierJB, MurisonR. Restoring psychology's role in peptic ulcer. Appl Psychol Health Well Being2013;5:5. CrossRef

100. CookDJ, FullerHD, GuyattGH, et al.Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group. N Engl J Med1994;330:377. CrossRef

101. CrooksCJ, WestJ, CardTR. Comorbidities affect risk of nonvariceal upper gastrointestinal bleeding. Gastroenterology2013;144:1384, 93 e1‐2; quiz e18‐9. CrossRef

102. MadsenKR, LorentzenK, ClausenN, et al.Guideline for stress ulcer prophylaxis in the intensive care unit. Dan Med J2014;61:C4811.

103. YachimskiP, FarrellE, HuntD, et al.Proton pump inhibitors for prophylaxis of nosocomial upper gastrointestinal tract bleeding: effect of standardized guidelines on prescribing practice. Arch Intern Med2010;170:779. CrossRef

104. WermelingM, HimmelW, BehrensG, et al.Why do GPs continue inappropriate hospital prescriptions of proton pump inhibitors? A qualitative study. Eur J Gen Pract2014;20:174. CrossRef

105. LangmanMJ, CookeAR. Gastric and duodenal ulcer and their associated diseases. Lancet1976;1:680. CrossRef

106. KellowJE, TaoZ, PiperDW. Ventilatory function in chronic peptic ulcer. A controlled study of ventilatory function in patients with gastric and duodenal ulcer. Gastroenterology1986;91:590.

107. SiringoS, BurroughsAK, BolondiL, et al.Peptic ulcer and its course in cirrhosis: an endoscopic and clinical prospective study. J Hepatol1995;22:633. CrossRef

108. KamalapornP, SobhonslidsukA, JatchavalaJ, et al.Factors predisposing to peptic ulcer disease in asymptomatic cirrhotic patients. Aliment Pharmacol Ther2005;21:1459. CrossRef

109. LoGH, YuHC, ChanYC, et al.The effects of eradication of Helicobacter pylori on the recurrence of duodenal ulcers in patients with cirrhosis. Gastrointest Endosc2005;62:350. CrossRef

110. GautamA. Gastrointestinal complications following transplantation. Surg Clin North Am2006;86:1195, vii. CrossRef

111. PonticelliC, PasseriniP. Gastrointestinal complications in renal transplant recipients. Transpl Int2005;18:643. CrossRef

112. BaronJH. The relationship between basal and maximum acid output in normal subjects and patients with duodenal ulcer. Clin Sci1963;24:357.

113. FeldmanM, BarnettC. Fasting gastric pH and its relationship to true hypochlorhydria in humans. Dig Dis Sci1991;36:866. CrossRef

114. JanssenM, DijkmansBA, VandenbrouckeJP, et al.Achlorhydria does not protect against benign upper gastrointestinal ulcers during NSAID use. Dig Dis Sci1994;39:362. CrossRef

115. ChernerJA, JensenRT, DuboisA, et al.Gastrointestinal dysfunction in systemic mastocytosis. A prospective study. Gastroenterology1988;95:657.

116. SamloffIM. Peptic ulcer: the many proteinases of aggression. Gastroenterology1989;96(2 Pt 2 Suppl):586.

117. CameronAJ, HigginsJA. Linear gastric erosion. A lesion associated with large diaphragmatic hernia and chronic blood loss anemia. Gastroenterology1986;91:338.

118. BlairAJ3rd, FeldmanM, BarnettC, et al.Detailed comparison of basal and food‐stimulated gastric acid secretion rates and serum gastrin concentrations in duodenal ulcer patients and normal subjects. J Clin Invest1987;79:582. CrossRef

119. MerkiHS, FimmelCJ, WaltRP, et al.Pattern of 24 hour intragastric acidity in active duodenal ulcer disease and in healthy controls. Gut1988;29:1583. CrossRef

120. HarrisAW, GummettPA, PhullPS, et al.Recurrence of duodenal ulcer after Helicobacter pylori eradication is related to high acid output. Aliment Pharmacol Ther1997;11:331. CrossRef

121. HoganDL, RapierRC, DreilingerA, et al.Duodenal bicarbonate secretion: eradication of Helicobacter pylori and duodenal structure and function in humans. Gastroenterology1996;110:705. CrossRef

122. WyattJI, RathboneBJ, SobalaGM, et al.Gastric epithelium in the duodenum: its association with Helicobacter pylori and inflammation. J Clin Pathol1990;43:981. CrossRef

123. GrossmanMI, KirsnerJB, GillespieIE. Basal and histalog‐stimulated gastric secretion in control subjects and in patients with peptic ulcer or gastric cancer. Gastroenterology1963;45:14.

124. Van ZantenSJ, DixonMF, LeeA. The gastric transitional zones: neglected links between gastroduodenal pathology and helicobacter ecology. Gastroenterology1999;116:1217. CrossRef

125. WarrenJR, MarshallBJ. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet1983;1:1273.

126. WeeksDL, EskandariS, ScottDR, et al.A H+‐gated urea channel: the link between Helicobacter pylori urease and gastric colonization. Science2000;287:482. CrossRef

127. DixonMF, GentaRM, YardleyJH, et al.Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol1996;20:1161. CrossRef

128. LeviS, BeardshallK, HaddadG, et al.Campylobacter pylori and duodenal ulcers: the gastrin link. Lancet1989;1:1167. CrossRef

129. MossSF, LegonS, BishopAE, et al.Effect of Helicobacter pylori on gastric somatostatin in duodenal ulcer disease. Lancet1992;340:930. CrossRef

130. GillenD, el OmarEM, WirzAA, et al.The acid response to gastrin distinguishes duodenal ulcer patients from Helicobacter pylori‐infected healthy subjects. Gastroenterology1998;114:50. CrossRef

131. HamletA, OlbeL. The influence of Helicobacter pylori infection on postprandial duodenal acid load and duodenal bulb pH in humans. Gastroenterology1996;111:391. CrossRef

132. KhulusiS, BadveS, PatelP, et al.Pathogenesis of gastric metaplasia of the human duodenum: role of Helicobacter pylori, gastric acid, and ulceration. Gastroenterology1996;110:452. CrossRef

133. BurkittMD, VarroA, PritchardDM. Importance of gastrin in the pathogenesis and treatment of gastric tumors. World J Gastroenterol2009;15:1. CrossRef

134. CorreaP, HaenszelW, CuelloC, et al.A model for gastric cancer epidemiology. Lancet1975;2:58. CrossRef

135. AthertonJC. The pathogenesis of Helicobacter pylori‐induced gastro‐duodenal diseases. Annu Rev Pathol2006;1:63. CrossRef

136. BassoD, ZambonCF, LetleyDP, et al.Clinical relevance of Helicobacter pylori cagA and vacA gene polymorphisms. Gastroenterology2008;135:91. CrossRef

137. OdenbreitS, PulsJ, SedlmaierB, et al.Translocation of Helicobacter pylori CagA into gastric epithelial cells by type IV secretion. Science2000;287:1497. CrossRef

138. ArgentRH, KiddM, OwenRJ, et al.Determinants and consequences of different levels of CagA phosphorylation for clinical isolates of Helicobacter pylori. Gastroenterology2004;127:514. CrossRef

139. KwokT, ZablerD, UrmanS, et al.Helicobacter exploits integrin for type IV secretion and kinase activation. Nature2007;449:862. CrossRef

140. VialaJ, ChaputC, BonecaIG, et al.Nod1 responds to peptidoglycan delivered by the Helicobacter pylori cag pathogenicity island. Nat Immunol2004;5:1166. CrossRef

141. AthertonJC, CaoP, PeekRMJr, et al.Mosaicism in vacuolating cytotoxin alleles of Helicobacter pylori. Association of specific vacA types with cytotoxin production and peptic ulceration. J Biol Chem1995;270:17771. CrossRef

142. RheadJL, LetleyDP, MohammadiM, et al.A new Helicobacter pylori vacuolating cytotoxin determinant, the intermediate region, is associated with gastric cancer. Gastroenterology2007;133:926. CrossRef

143. BorenT, FalkP, RothKA, et al.Attachment of Helicobacter pylori to human gastric epithelium mediated by blood group antigens. Science1993;262:1892. CrossRef

144. GerhardM, LehnN, NeumayerN, et al.Clinical relevance of the Helicobacter pylori gene for blood‐group antigen‐binding adhesin. Proc Natl Acad Sci U S A1999;96:12778. CrossRef

145. YamaokaY, KikuchiS, el‐ZimaityHM, et al.Importance of Helicobacter pylori oipA in clinical presentation, gastric inflammation, and mucosal interleukin 8 production. Gastroenterology2002;123:414. CrossRef

146. LuH, HsuPI, GrahamDY, et al.Duodenal ulcer promoting gene of Helicobacter pylori. Gastroenterology2005;128:833. CrossRef

147. HusseinNR, ArgentRH, MarxCK, et al.Helicobacter pylori dupA is polymorphic, and its active form induces proinflammatory cytokine secretion by mononuclear cells. J Infect Dis2010;202:261. CrossRef

148. ShiotaS, MatsunariO, WatadaM, et al.Systematic review and meta‐analysis: the relationship between the Helicobacter pylori dupA gene and clinical outcomes. Gut Pathog2010;2:13. CrossRef

149. MacarthurM, HoldGL, El‐OmarEM. Inflammation and Cancer II. Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy. Am J Physiol Gastrointest Liver Physiol2004;286:G515. CrossRef

150. El‐OmarEM, CarringtonM, ChowWH, et al.Interleukin‐1 polymorphisms associated with increased risk of gastric cancer. Nature2000;404:398. CrossRef

151. PatelMK, TromblyMI, Kurt‐JonesEA. Innate immune responses to Helicobacter pylori infection: an overview. Methods Mol Biol2012;921:205. CrossRef

152. MullerA, SolnickJV. Inflammation, immunity, and vaccine development for Helicobacter pylori. Helicobacter2011;16(Suppl 1):26. CrossRef

153. RobinsonK, AthertonJC. Chapter 38 – Helicobacter pylori: the role of the immune response in pathogenesis. In: KaufmannSHE, RouseBT, SacksDL(eds). Immunology of Infectious Diseases. Washington, DC: ASM Press; 2011: 337.

154. RobinsonK, KenefeckR, PidgeonEL, et al.Helicobacter pylori‐induced peptic ulcer disease is associated with inadequate regulatory T cell responses. Gut2008;57:1375. CrossRef

155. ChenTS, LeeYC, LiFY, et al.Smoking and hyperpepsinogenemia are associated with increased risk for duodenal ulcer in Helicobacter pylori‐infected patients. J Clin Gastroenterol2005;39:699. CrossRef

156. DikmanA, SanyalS, von AlthannC, et al.A randomized, placebo‐controlled study of the effects of naproxen, aspirin, celecoxib or clopidogrel on gastroduodenal mucosal healing. Aliment Pharmacol Ther2009;29:781. CrossRef

157. HawkeyCJ. Nonsteroidal anti‐inflammatory drug gastropathy. Gastroenterology2000;119:521. CrossRef

158. TakeuchiK. Pathogenesis of NSAID‐induced gastric damage: importance of cyclooxygenase inhibition and gastric hypermotility. World J Gastroenterol2012;18:2147. CrossRef

159. SchnitzerTJ, BurmesterGR, MyslerE, et al.Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet2004;364:665. CrossRef

160. LaineL, CurtisSP, CryerB, et al.Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long‐term (MEDAL) programme: a randomised comparison. Lancet2007;369:465. CrossRef

161. HawkeyCJ, WeinsteinWM, SmalleyW, et al.Effect of risk factors on complicated and uncomplicated ulcers in the TARGET lumiracoxib outcomes study. Gastroenterology2007;133:57. CrossRef

162. RostomA, MuirK, DubeC, et al.Gastrointestinal safety of cyclooxygenase‐2 inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol2007;5:818, 28 e1‐5; quiz 768. CrossRef

163. McGettiganP, HenryD. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA2006;296:1633. CrossRef

164. RostomA, MuirK, DubeC, et al.Prevention of NSAID‐related upper gastrointestinal toxicity: a meta‐analysis of traditional NSAIDs with gastroprotection and COX‐2 inhibitors. Drug Healthc Patient Saf2009;1:47. CrossRef

165. van der LindenMW, van der BijS, WelsingP, et al.The balance between severe cardiovascular and gastrointestinal events among users of selective and non‐selective non‐steroidal anti‐inflammatory drugs. Ann Rheum Dis2009;68:668. CrossRef

166. ElliottSN, WallaceJL. Nitric oxide, bacteria and ulcer healing. In: HuntRH, TytgatGNJ(eds). Helicobacter pylori – Basic Mechanisms to Clinical Cure. Dordrecht, Netherlands: Springer Netherlands; 1996: 132.

167. LewisSC, LangmanMJ, LaporteJR, et al.Dose‐response relationships between individual nonaspirin nonsteroidal anti‐inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta‐analysis based on individual patient data. Br J Clin Pharmacol2002;54:320. CrossRef

168. GisbertJP, CalvetX. Review article: Helicobacter pylori‐negative duodenal ulcer disease. Aliment Pharmacol Ther2009;30:791. CrossRef

169. MalatyHM, EngstrandL, PedersenNL, et al.Helicobacter pylori infection: genetic and environmental influences. A study of twins. Ann Intern Med1994;120:982. CrossRef

170. YamamotoF, CidE, YamamotoM, et al.ABO research in the modern era of genomics. Transfus Med Rev2012;26:103. CrossRef

171. EdgrenG, HjalgrimH, RostgaardK, et al.Risk of gastric cancer and peptic ulcers in relation to ABO blood type: a cohort study. Am J Epidemiol2010;172:1280. CrossRef

172. MoranAP. Relevance of fucosylation and Lewis antigen expression in the bacterial gastroduodenal pathogen Helicobacter pylori. Carbohydr Res2008;343:1952. CrossRef

173. MalatyHM, GrahamDY, IsakssonI, et al.Are genetic influences on peptic ulcer dependent or independent of genetic influences for Helicobacter pylori infection?Arch Intern Med2000;160:105. CrossRef

174. SnaithA, El‐OmarEM. Helicobacter pylori: host genetics and disease outcomes. Expert Rev Gastroenterol Hepatol2008;2:577. CrossRef

175. SugimotoM, YamaokaY, FurutaT. Influence of interleukin polymorphisms on development of gastric cancer and peptic ulcer. World J Gastroenterol2010;16:1188. CrossRef

176. MusumbaC, PritchardDM, PirmohamedM. Review article: cellular and molecular mechanisms of NSAID‐induced peptic ulcers. Aliment Pharmacol Ther2009;30:517. CrossRef

177. ShiotaniA, SakakibaraT, NomuraM, et al.Aspirin‐induced peptic ulcer and genetic polymorphisms. J Gastroenterol Hepatol2010;25(Suppl 1):S31. CrossRef

178. AzumaT, KonishiJ, ItoY, et al.Genetic differences between duodenal ulcer patients who were positive or negative for Helicobacter pylori. J Clin Gastroenterol1995;21(Suppl 1):S151.

179. BardhanKD. Intermittent treatment of duodenal ulcer for long term medical management. Postgrad Med J1988;64(Suppl 1):40.

180. KoivistoTT, VoutilainenME, FarkkilaMA. Symptoms, endoscopic findings and histology predicting symptomatic benefit of Helicobacter pylori eradication. Scand J Gastroenterol2008;43:810. CrossRef

181. MiwaH, SakakiN, SuganoK, et al.Recurrent peptic ulcers in patients following successful Helicobacter pylori eradication: a multicenter study of 4940 patients. Helicobacter2004;9:9. CrossRef

182. ShiotaniA, NishiokaS, IguchiM, et al.Duodenal erosions after eradication of Helicobacter pylori infection. Gastrointest Endosc2001;54:448. CrossRef

183. LaineL, HopkinsRJ, GirardiLS. Has the impact of Helicobacter pylori therapy on ulcer recurrence in the United States been overstated? A meta‐analysis of rigorously designed trials. Am J Gastroenterol1998;93:1409.

184. BulajZJ, AjiokaRS, PhillipsJD, et al.Disease‐related conditions in relatives of patients with hemochromatosis. N Engl J Med2000;343:1529. CrossRef

185. SollAH, WeinsteinWM, KurataJ, et al.Nonsteroidal anti‐inflammatory drugs and peptic ulcer disease. Ann Intern Med1991;114:307. CrossRef

186. LarkaiEN, SmithJL, LidskyMD, et al.Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti‐inflammatory drug use. Am J Gastroenterol1987;82:1153.

187. ChanFK, HungLC, SuenBY, et al.Celecoxib versus diclofenac plus omeprazole in high‐risk arthritis patients: results of a randomized double‐blind trial. Gastroenterology2004;127:1038. CrossRef

188. WongGL, WongVW, ChanY, et al.High incidence of mortality and recurrent bleeding in patients with Helicobacter pylori‐negative idiopathic bleeding ulcers. Gastroenterology2009;137:525. CrossRef

189. BardhanKD, ColeDS, HawkinsBW, et al.Does treatment with cimetidine extended beyond initial healing of duodenal ulcer reduce the subsequent relapse rate?Br Med J (Clin Res Ed)1982;284:621. CrossRef

190. Gudmand‐HoyerE, JensenKB, KragE, et al.Prophylactic effect of cimetidine in duodenal ulcer disease. Br Med J1978;1:1095. CrossRef

191. The ACG Committee on FDA‐Related Matters. Current status of maintenance therapy in peptic ulcer disease. Am J Gastroenterol1988;83:607.

192. BoydEJ, WilsonJA, WormsleyKG. The fate of asymptomatic recurrences of duodenal ulcer. Scand J Gastroenterol1984;19:808.

193. WolosinJD, GertlerSL, PetersonWL, et al.Gastric ulcer recurrence: follow‐up of a double‐blind, placebo‐controlled trial. J Clin Gastroenterol1989;11:12. CrossRef

194. LongstrethGF, ThompsonWG, CheyWD, et al.Functional bowel disorders. Gastroenterology2006;130:1480. CrossRef

195. TalleyNJ, VakilNB, MoayyediP. American Gastroenterological Association technical review on the evaluation of dyspepsia. Gastroenterology2005;129:1756. CrossRef

196. TalleyNJ, American GastroenterologicalA. American Gastroenterological Association medical position statement: evaluation of dyspepsia. Gastroenterology2005;129:1753. CrossRef

197. WerdmullerBF, van der PuttenAB, LoffeldRJ. The clinical presentation of peptic ulcer disease. Neth J Med1997;50:115. CrossRef

198. MoayyediP, TalleyNJ, FennertyMB, et al.Can the clinical history distinguish between organic and functional dyspepsia?JAMA2006;295:1566. CrossRef

199. DewMJ. Asymptomatic peptic ulcer disease. Br Med J (Clin Res Ed)1987;295:401.

200. LuCL, ChangSS, WangSS, et al.Silent peptic ulcer disease: frequency, factors leading to "silence," and implications regarding the pathogenesis of visceral symptoms. Gastrointest Endosc2004;60:34. CrossRef

201. HirschowitzBI, SimmonsJL, JohnsonLF, et al.Risk factors for esophagitis in extreme acid hypersecretors with and without Zollinger‐Ellison syndrome. Clin Gastroenterol Hepatol2004;2:220. CrossRef

202. McCollKE, DicksonA, El‐NujumiA, et al.Symptomatic benefit 1‐3 years after H. pylori eradication in ulcer patients: impact of gastroesophageal reflux disease. Am J Gastroenterol2000;95:101.

203. SteigmannF, ShulmanB. The time of healing of gastric ulcers: implications as to therapy. Gastroenterology1952;20:20.

204. NewtonEB, VerslandMR, SepeTE. Giant duodenal ulcers. World J Gastroenterol2008;14:4995. CrossRef

205. DrummB, RhoadsJM, StringerDA, et al.Peptic ulcer disease in children: etiology, clinical findings, and clinical course. Pediatrics1988;82(3 Pt 2):410.

206. FordAC, MoayyediP. Current guidelines for dyspepsia management. Dig Dis2008;26:225. CrossRef

207. TalleyNJ, VakilN. Practice Parameters Committee of the American College of G. Guidelines for the management of dyspepsia. Am J Gastroenterol2005;100:2324. CrossRef

208. National Institute for Health and Care Excellence. Dyspepsia and gastro‐oesophageal reflux disease. NICE clinical guideline 184. London: NICE; 2014.

209. HarmonRC, PeuraDA. Evaluation and management of dyspepsia. Therap Adv Gastroenterol2010;3:87. CrossRef

210. ReimerC, SondergaardB, HilstedL, et al.Proton‐pump inhibitor therapy induces acid‐related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology2009;137:80, 7 e1. CrossRef

211. GuptaS, McQuaidK. Management of nonsteroidal, anti‐inflammatory, drug‐associated dyspepsia. Gastroenterology2005;129:1711. CrossRef

212. MalfertheinerP, ChanFK, McCollKE. Peptic ulcer disease. Lancet2009;374:1449. CrossRef

213. GrahamDY, RuggeM. Clinical practice: diagnosis and evaluation of dyspepsia. J Clin Gastroenterol2010;44:167. CrossRef

214. KoletzkoS, JonesNL, GoodmanKJ, et al.Evidence‐based guidelines from ESPGHAN and NASPGHAN for Helicobacter pylori infection in children. J Pediatr Gastroenterol Nutr2011;53:230.

215. LaineL, JensenDM. Management of patients with ulcer bleeding. Am J Gastroenterol2012;107:345, quiz 61. CrossRef

216. TonkicA, TonkicM, LehoursP, et al.Epidemiology and diagnosis of Helicobacter pylori infection. Helicobacter2012;17(Suppl 1):1. CrossRef

217. LoughreyMB, JohnstonBT. Guidance on the effective use of upper gastrointestinal histopathology. Frontline Gastroenterol2014;5:88. CrossRef

218. RuggeM, CorreaP, Di MarioF, et al.OLGA staging for gastritis: a tutorial. Dig Liver Dis2008;40:650. CrossRef

219. MegraudF, LehoursP. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev2007;20:280. CrossRef

220. GisbertJP, AbrairaV. Accuracy of Helicobacter pylori diagnostic tests in patients with bleeding peptic ulcer: a systematic review and meta‐analysis. Am J Gastroenterol2006;101:848. CrossRef

221. Participants in the Paris Workshop. The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002. Gastrointest Endosc2003;58(6 Suppl):S3. CrossRef

222. Endoscopic Classification Review Group. Update on the Paris classification of superficial neoplastic lesions in the digestive tract. Endoscopy2005;37:570. CrossRef

223. GrahamDY, SchwartzJT, CainGD, et al.Prospective evaluation of biopsy number in the diagnosis of esophageal and gastric carcinoma. Gastroenterology1982;82:228.

224. El AbiadR, GerkeH. Gastric cancer: endoscopic diagnosis and staging. Surg Oncol Clin N Am2012;21:1. CrossRef

225. BrambleMG, SuvakovicZ, HunginAP. Detection of upper gastrointestinal cancer in patients taking antisecretory therapy prior to gastroscopy. Gut2000;46:464. CrossRef

226. WaymanJ, HayesN, GriffinSM. The response of early gastric cancer to proton‐pump inhibitors. N Engl J Med1998;338:1924. CrossRef

227. DickeyW, KennyBD, McConnellJB. Effect of proton pump inhibitors on the detection of Helicobacter pylori in gastric biopsies. Aliment Pharmacol Ther1996;10:289. CrossRef

228. ToddJA, RichardsCJ, DixonA, et al.Gastric ulcer and malignancy – is there a need for follow‐up endoscopy?Aliment Pharmacol Ther2004;19:989. CrossRef

229. ASGE Standards of Practice Committee, BanerjeeS, CashBD, et al.The role of endoscopy in the management of patients with peptic ulcer disease. Gastrointest Endosc2010;71:663. CrossRef

230. BockOA, ArapakisG, WittsLJ, et al.The serum pepsinogen level with special reference to the histology of the gastric mucosa. Gut1963;4:106. CrossRef

231. SamloffIM. Pepsinogens I and II: purification from gastric mucosa and radioimmunoassay in serum. Gastroenterology1982;82:26.

232. AgreusL, KuipersEJ, KupcinskasL, et al.Rationale in diagnosis and screening of atrophic gastritis with stomach‐specific plasma biomarkers. Scand J Gastroenterol2012;47:136. CrossRef

233. LejaM, WexT, MalfertheinerP. Markers for gastric cancer premalignant lesions: where do we go?Dig Dis2012;30:268. CrossRef

234. FordA, DelaneyB, FormanD, et al.Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst Rev2004;(4):CD003840.

235. SonnenbergA, TownsendWF. Costs of duodenal ulcer therapy with antibiotics. Arch Intern Med1995;155:922. CrossRef

236. MegraudF, CoenenS, VersportenA, et al.Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut2013;62:34. CrossRef

237. De FrancescoV, GiorgioF, HassanC, et al.Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis2010;19:409.

238. FischbachL, EvansEL. Meta‐analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first‐line therapies for Helicobacter pylori. Aliment Pharmacol Ther2007;26:343. CrossRef

239. O'ConnorA, Molina‐InfanteJ, GisbertJP, et al.Treatment of Helicobacter pylori infection 2013. Helicobacter2013;18(Suppl 1):58. CrossRef

240. GeorgopoulosS, PapastergiouV, XirouchakisE, et al.Nonbismuth quadruple "concomitant" therapy versus standard triple therapy, both of the duration of 10 days, for first‐line H. pylori eradication: a randomized trial. J Clin Gastroenterol2013;47:228. CrossRef

241. JavidG, ZargarSA, BhatK, et al.Efficacy and safety of sequential therapy versus standard triple therapy in Helicobacter pylori eradication in Kashmir India: a randomized comparative trial. Indian J Gastroenterol2013;32:190. CrossRef

242. DoreMP, MassiddaM, YilmazO, et al.Miocamycin‐containing triple therapy for H. pylori infection. Helicobacter2013;18:285. CrossRef

243. YanaiA, SakamotoK, AkanumaM, et al.Non‐bismuth quadruple therapy for first‐line Helicobacter pylori eradication: a randomized study in Japan. World J Gastrointest Pharmacol Ther2012;3:1. CrossRef

244. NishizawaT, SuzukiH, SuzukiM, et al.Proton pump inhibitor‐amoxicillin‐clarithromycin versus proton pump inhibitor‐amoxicillin‐metronidazole as first‐line Helicobacter pylori eradication therapy. J Clin Biochem Nutr2012;51:114. CrossRef

245. Gonzalez‐HuezoMS, Rojas‐SanchezA, Rosales‐SolisAA, et al.Helicobacter pylori eradication frequency with the conventional triple therapy in adult patients at the Centro Medico Issemym. Rev Gastroenterol Mex2012;77:114.

246. GisbertJP, McNichollAG. Maintenance of Helicobacter pylori eradication rates with triple therapy over 12 years in a Spanish hospital. Helicobacter2012;17:160. CrossRef

247. CosmeA, MontesM, MartosM, et al.Usefulness of antimicrobial susceptibility in the eradication of Helicobacter pylori. Clin Microbiol Infect2013;19:379. CrossRef

248. YoonJH, BaikGH, SohnKM, et al.Trends in the eradication rates of Helicobacter pylori infection for eleven years. World J Gastroenterol2012;18:6628. CrossRef

249. KimSY, LeeSW, HyunJJ, et al.Comparative study of Helicobacter pylori eradication rates with 5‐day quadruple "concomitant" therapy and 7‐day standard triple therapy. J Clin Gastroenterol2013;47:21. CrossRef

250. AngTL, WangL, AngD, et al.Is there still a role for empiric first‐line triple therapy using proton pump inhibitor, amoxicillin and clarithromycin for Helicobacter pylori infection in Singapore? Results of a time trend analysis. J Dig Dis2013;14:100. CrossRef

251. PrasertpetmaneeS, MahachaiV, VilaichoneRK. Improved efficacy of proton pump inhibitor – amoxicillin – clarithromycin triple therapy for Helicobacter pylori eradication in low clarithromycin resistance areas or for tailored therapy. Helicobacter2013;18:270. CrossRef

252. MalfertheinerP, MegraudF, O'MorainCA, et al.Management of Helicobacter pylori infection – the Maastricht IV/ Florence Consensus Report. Gut2012;61:646. CrossRef

253. FuccioL, MinardiME, ZagariRM, et al.Meta‐analysis: duration of first‐line proton‐pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med2007;147:553. CrossRef

254. VilloriaA. Acid‐related diseases: are higher doses of proton pump inhibitors more effective in the treatment of Helicobacter pylori infection?Gastroenterol Hepatol2008;31:546. CrossRef

255. CalvetX, GarciaN, LopezT, et al.A meta‐analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther2000;14:603. CrossRef

256. McCollKE. Clinical practice. Helicobacter pylori infection. N Engl J Med2010;362:1597. CrossRef

257. GrahamDY, FischbachL. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut2010;59:1143. CrossRef

258. de BoerWA, DriessenWM, PottersVP, et al.Randomized study comparing 1 with 2 weeks of quadruple therapy for eradicating Helicobacter pylori. Am J Gastroenterol1994;89:1993.

259. EssaAS, KramerJR, GrahamDY, et al.Meta‐analysis: four‐drug, three‐antibiotic, non‐bismuth‐containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication. Helicobacter2009;14:109. CrossRef

260. LaineL, HuntR, El‐ZimaityH, et al.Bismuth‐based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol2003;98:562. CrossRef

261. SalazarCO, CardenasVM, ReddyRK, et al.Greater than 95% success with 14‐day bismuth quadruple anti‐ Helicobacter pylori therapy: a pilot study in US Hispanics. Helicobacter2012;17:382. CrossRef

262. UygunA, OzelAM, SivriB, et al.Efficacy of a modified sequential therapy including bismuth subcitrate as first‐line therapy to eradicate Helicobacter pylori in a Turkish population. Helicobacter2012;17:486. CrossRef

263. LutherJ, HigginsPD, SchoenfeldPS, et al.Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: systematic review and meta‐analysis of efficacy and tolerability. Am J Gastroenterol2010;105:65. CrossRef

264. FakheriH, BariZ. Sardarian H. A modified bismuth‐containing quadruple therapy including a short course of furazolidone for Helicobacter pylori eradication after sequential therapy failure. Helicobacter2012;17:264. CrossRef

265. YoonJH, BaikGH, KimYS, et al.Comparison of the eradication rate between 1‐ and 2‐week bismuth‐containing quadruple rescue therapies for Helicobacter pylori eradication. Gut Liver2012;6:434. CrossRef

266. KuoCH, HsuPI, KuoFC, et al.Comparison of 10 day bismuth quadruple therapy with high‐dose metronidazole or levofloxacin for second‐line Helicobacter pylori therapy: a randomized controlled trial. J Antimicrob Chemother2013;68:222. CrossRef

267. MalfertheinerP, BazzoliF, DelchierJC, et al.Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin‐based triple therapy: a randomised, open‐label, non‐inferiority, phase 3 trial. Lancet2011;377:905. CrossRef

268. GrahamDY, ShiotaniA. Which Therapy for Helicobacter pylori Infection?Gastroenterology2012;143:10. CrossRef

269. QianJ, YeF, ZhangJ, et al.Levofloxacin‐containing triple and sequential therapy or standard sequential therapy as the first line treatment for Helicobacter pylori eradication in China. Helicobacter2012;17:478. CrossRef

270. ShahA, JavidG, ZargarSA, et al.Safety and efficacy of 1‐week levofloxacin‐based triple therapy in first‐line treatment for Helicobacter pylori‐related peptic ulcer disease in Kashmir, India. Indian J Gastroenterol2013;32:32. CrossRef

271. FedericoA, NardoneG, GravinaAG, et al.Efficacy of 5‐day levofloxacin‐containing concomitant therapy in eradication of Helicobacter pylori infection. Gastroenterology2012;143:55, quize e13‐4. CrossRef

272. Cuadrado‐LavinA, Salcines‐CaviedesJR, CarrascosaMF, et al.Levofloxacin versus clarithromycin in a 10 day triple therapy regimen for first‐line Helicobacter pylori eradication: a single‐blind randomized clinical trial. J Antimicrob Chemother2012;67:2254. CrossRef

273. ChuahSK, TaiWC, HsuPI, et al.The efficacy of second‐line anti‐Helicobacter pylori therapy using an extended 14‐day levofloxacin/amoxicillin/proton‐pump inhibitor treatment – a pilot study. Helicobacter2012;17:374. CrossRef

274. Di CaroS, FiniL, DaoudY, et al.Levofloxacin/amoxicillin‐based schemes vs quadruple therapy for Helicobacter pylori eradication in second‐line. World J Gastroenterol2012;18:5669. CrossRef

275. GisbertJP, Perez‐AisaA, BermejoF, et al.Second‐line therapy with levofloxacin after failure of treatment to eradicate helicobacter pylori infection: time trends in a Spanish Multicenter Study of 1000 patients. J Clin Gastroenterol2013;47:130. CrossRef

276. ChuahSK, HsuPI, ChangKC, et al.Randomized comparison of two non‐bismuth‐containing second‐line rescue therapies for Helicobacter pylori. Helicobacter2012;17:216. CrossRef

277. BasuPP, RayapudiK, PacanaT, et al.A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. Am J Gastroenterol2011;106:1970. CrossRef

278. LiouJM, ChenCC, ChenMJ, et al.Sequential versus triple therapy for the first‐line treatment of Helicobacter pylori: a multicentre, open‐label, randomised trial. Lancet2013;381:205. CrossRef

279. GreenbergER, AndersonGL, MorganDR, et al.14‐day triple, 5‐day concomitant, and 10‐day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet2011;378:507. CrossRef

280. ZulloA, De FrancescoV, HassanC, et al.Modified sequential therapy regimens for Helicobacter pylori eradication: a systematic review. Dig Liver Dis2013;45:18. CrossRef

281. ZulloA, HassanC, RidolaL, et al.Standard triple and sequential therapies for Helicobacter pylori eradication: an update. Eur J Intern Med2013;24:16. CrossRef

282. WuDC, HsuPI, WuJY, et al.Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection. Clin Gastroenterol Hepatol2010;8:36. CrossRef

283. McNichollAG, MarinAC, Molina‐InfanteJ, et al.Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice. Gut2014;63:244.

284. HuangYK, WuMC, WangSS, et al.Lansoprazole‐based sequential and concomitant therapy for the first‐line Helicobacter pylori eradication. J Dig Dis2012;13:232. CrossRef

285. LimJH, LeeDH, ChoiC, et al.Clinical outcomes of two‐week sequential and concomitant therapies for Helicobacter pylori eradication: a randomized pilot study. Helicobacter2013;18:180. CrossRef

286. GisbertJP, CalvetX. Update on non‐bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol2012;5:23. CrossRef

287. SachdevaA, NagpalJ. Meta‐analysis: efficacy of bovine lactoferrin in Helicobacter pylori eradication. Aliment Pharmacol Ther2009;29:720. CrossRef

288. ZouJ, DongJ, YuX. Meta‐analysis: Lactobacillus containing quadruple therapy versus standard triple first‐line therapy for Helicobacter pylori eradication. Helicobacter2009;14:97.

289. FranceschiF, CazzatoA, NistaEC, et al.Role of probiotics in patients with Helicobacter pylori infection. Helicobacter2007;12(Suppl 2):59. CrossRef

290. ArmuzziA, CremoniniF, BartolozziF, et al.The effect of oral administration of Lactobacillus GG on antibiotic‐associated gastrointestinal side‐effects during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther2001;15:163. CrossRef

291. SzajewskaH, HorvathA, PiwowarczykA. Meta‐analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther2010;32:1069. CrossRef

292. SongMJ, ParkDI, ParkJH, et al.The effect of probiotics and mucoprotective agents on PPI‐based triple therapy for eradication of Helicobacter pylori. Helicobacter2010;15:206. CrossRef

293. CindorukM, ErkanG, KarakanT, et al.Efficacy and safety of Saccharomyces boulardii in the 14‐day triple anti‐Helicobacter pylori therapy: a prospective randomized placebo‐controlled double‐blind study. Helicobacter2007;12:309. CrossRef

294. CremoniniF, Di CaroS, CovinoM, et al.Effect of different probiotic preparations on anti‐helicobacter pylori therapy‐related side effects: a parallel group, triple blind, placebo‐controlled study. Am J Gastroenterol2002;97:2744. CrossRef

295. NseirW, DiabH, MahamidM, et al.Randomised clinical trial: simvastatin as adjuvant therapy improves significantly the Helicobacter pylori eradication rate – a placebo‐controlled study. Aliment Pharmacol Ther2012;36:231. CrossRef

296. BedwellJ, HoltonJ, VairaD, et al.In vitro killing of Helicobacter pylori with photodynamic therapy. Lancet1990;335:1287. CrossRef

297. Calvino‐FernandezM, Garcia‐FresnadilloD, Benito‐MartinezS, et al.Helicobacter pylori inactivation and virulence gene damage using a supported sensitiser for photodynamic therapy. Eur J Med Chem2013;68:284. CrossRef

298. SuttonP, ChionhYT. Why can't we make an effective vaccine against Helicobacter pylori?Expert Rev Vaccines2013;12:433. CrossRef

299. SuzukiT, MatsuoK, ItoH, et al.Smoking increases the treatment failure for Helicobacter pylori eradication. Am J Med2006;119:217. CrossRef

300. FockKM, AngTL, BeeLC, et al.Proton pump inhibitors: do differences in pharmacokinetics translate into differences in clinical outcomes?Clin Pharmacokinet2008;47:1. CrossRef

301. FurutaT, OhashiK, KosugeK, et al.CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther1999;65:552. CrossRef

302. SchwabM, SchaeffelerE, KlotzU, et al.CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole‐based quadruple therapy for eradication of Helicobacter pylori. Clin Pharmacol Ther2004;76:201. CrossRef

303. FurutaT, ShiraiN, TakashimaM, et al.Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin. Pharmacogenetics2001;11:341. CrossRef

304. GrahamDY, JavedSU, KeihanianS, et al.Dual proton pump inhibitor plus amoxicillin as an empiric anti‐H. pylori therapy: studies from the United States. J Gastroenterol2010;45:816. CrossRef

305. SuP, LiY, LiH, et al.Antibiotic resistance of Helicobacter pylori isolated in the Southeast Coastal Region of China. Helicobacter2013;18:274. CrossRef

306. LeeJW, KimN, KimJM, et al.Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012. Helicobacter2013;18:206. CrossRef

307. SeckA, BurucoaC, DiaD, et al.Primary antibiotic resistance and associated mechanisms in Helicobacter pylori isolates from Senegalese patients. Ann Clin Microbiol Antimicrob2013;12:3. CrossRef

308. McNultyCA, LasseterG, ShawI, et al.Is Helicobacter pylori antibiotic resistance surveillance needed and how can it be delivered?Aliment Pharmacol Ther2012;35:1221. CrossRef

309. de BoerWA, TytgatGN. The best therapy for Helicobacter pylori infection: should efficacy or side‐effect profile determine our choice?Scand J Gastroenterol1995;30:401. CrossRef

310. FischbachLA, van ZantenS, DickasonJ. Meta‐analysis: the efficacy, adverse events, and adherence related to first‐line anti‐Helicobacter pylori quadruple therapies. Aliment Pharmacol Ther2004;20:1071. CrossRef

311. HuntRH, XiaoSD, MegraudF, et al.Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline. J Gastrointestin Liver Dis2011;20:299.

312. FockKM, KatelarisP, SuganoK, et al.Second Asia‐Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol2009;24:1587. CrossRef

313. AsakaM, KatoM, TakahashiS, et al.Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter2010;15:1. CrossRef

314. CheyWD, WongBC. Practice Parameters Committee of the American College of G. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol2007;102:1808. CrossRef

315. Chinese Society of Gastroenterology Chinese Study Group on Helicobacter pylori, LiuWZ, XieY, et al.Fourth Chinese National Consensus Report on the management of Helicobacter pylori infection. J Dig Dis2013;14:211. CrossRef

316. YanTL, HuQD, ZhangQ, et al.National rates of Helicobacter pylori recurrence are significantly and inversely correlated with human development index. Aliment Pharmacol Ther2013;37:963. CrossRef

317. MarinAC, McNichollAG, GisbertJP. A review of rescue regimens after clarithromycin‐containing triple therapy failure (for Helicobacter pylori eradication). Expert Opin Pharmacother2013;14:843. CrossRef

318. GisbertJP, Perez‐AisaA, RodrigoL, et al.Third‐line rescue therapy with bismuth‐containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for H. pylori infection. Dig Dis Sci2014;59:383. CrossRef

319. GrahamDY, LeeYC, WuMS. Rational Helicobacter pylori therapy: evidence‐based medicine rather than medicine‐based evidence. Clin Gastroenterol Hepatol2014;12:177. CrossRef

320. VakilN, VairaD. Treatment for H. pylori infection: new challenges with antimicrobial resistance. J Clin Gastroenterol2013;47:383. CrossRef

321. IwanczakF, IwanczakB. Treatment of Helicobacter pylori infection in the aspect of increasing antibiotic resistance. Adv Clin Exp Med2012;21:671.

322. ShiotaS, YamaokaY. Strategy for the treatment of Helicobacter pylori infection. Curr Pharm Des2017;20:4489. CrossRef

323. MalfertheinerP, SelgradM, BornscheinJ. Helicobacter pylori: clinical management. Curr Opin Gastroenterol2012;28:608. CrossRef

324. MossSF. How can we rationally select helicobacter pylori therapy without resistance data?Clin Gastroenterol Hepatol2014;12:1578. CrossRef

325. YeomansND, TulassayZ, JuhaszL, et al.A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID‐associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med1998;338:719. CrossRef

326. AgrawalNM, CampbellDR, SafdiMA, et al.Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti‐inflammatory drug‐associated gastric ulcers: results of a double‐blind, randomized, multicenter study. NSAID‐Associated Gastric Ulcer Study Group. Arch Intern Med2000;160:1455. CrossRef

327. HawkeyCJ, KarraschJA, SzczepanskiL, et al.Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID‐induced Ulcer Management (OMNIUM) Study Group. N Engl J Med1998;338:727. CrossRef

328. Bianchi PorroG, LazzaroniM, ManzionnaG, et al.Omeprazole and sucralfate in the treatment of NSAID‐induced gastric and duodenal ulcer. Aliment Pharmacol Ther1998;12:355. CrossRef

329. LanzaFL, ChanFK, QuigleyEM. Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID‐related ulcer complications. Am J Gastroenterol2009;104:728. CrossRef

330. PietroiustiA, ForliniA, MagriniA, et al.Isolated H. pylori duodenal colonization and idiopathic duodenal ulcers. Am J Gastroenterol2008;103:55. CrossRef

331. SollAH, VakilNB. Work‐up for apparently H. pylori‐negative, NSAID‐negative ulcers. Figure in: Unusual causes of peptic ulcer disease. In: PostTW(ed). UpToDate. Waltham, MA: UpToDate. [accessed Dec 2013]. Copyright © 2015 UpToDate, Inc. For more information visit: www.uptodate.com.

332. LabenzJ, TillenburgB, PeitzU, et al.Helicobacter pylori augments the pH‐increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology1996;110:725. CrossRef

333. VerduEF, ArmstrongD, FraserR, et al.Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole. Gut1995;36:539. CrossRef

334. BardhanKD, NayyarAK, RoystonC. History in our lifetime: the changing nature of refractory duodenal ulcer in the era of histamine H2 receptor antagonists. Dig Liver Dis2003;35:529. CrossRef

335. BardhanKD. Is there any acid peptic disease that is refractory to proton pump inhibitors?Aliment Pharmacol Ther1993;7(Suppl 1):13, discussion 9‐31. CrossRef

336. GoldsteinJL, JohansonJF, HawkeyCJ, et al.Clinical trial: healing of NSAID‐associated gastric ulcers in patients continuing NSAID therapy – a randomized study comparing ranitidine with esomeprazole. Aliment Pharmacol Ther2007;26:1101. CrossRef

337. LanasA, RemachaB, SainzR, et al.Study of outcome after targeted intervention for peptic ulcer resistant to acid suppression therapy. Am J Gastroenterol2000;95:513. CrossRef

338. HirschowitzBI, LanasA. Intractable upper gastrointestinal ulceration due to aspirin in patients who have undergone surgery for peptic ulcer. Gastroenterology1998;114:883. CrossRef

339. HirschowitzBI, LanasA. Atypical and aggressive upper gastrointestinal ulceration associated with aspirin abuse. J Clin Gastroenterol2002;34:523. CrossRef

340. GoodmanAJ, KerriganDD, JohnsonAG. Effect of the pre‐operative response to H2 receptor antagonists on the outcome of highly selective vagotomy for duodenal ulcer. Br J Surg1987;74:897. CrossRef

341. Bianchi PorroG, ParenteF. Refractory duodenal ulcer: an emerging therapeutic problem]. Medicina (Firenze)1988;8:27.

342. BoltonJS, ConwayWC2nd.Postgastrectomy syndromes. Surg Clin North Am2011;91:1105. CrossRef

343. PalaniveluC, JaniK, RajanPS, et al.Laparoscopic management of acid peptic disease. Surg Laparosc Endosc Percutan Tech2006;16:312. CrossRef

344. YeomansND, LanasAI, TalleyNJ, et al.Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther2005;22:795. CrossRef

345. BrownTJ, HooperL, ElliottRA, et al.A comparison of the cost‐effectiveness of five strategies for the prevention of non‐steroidal anti‐inflammatory drug‐induced gastrointestinal toxicity: a systematic review with economic modelling. Health Technol Assess2006;10:iii, xi‐xiii, 1‐183. CrossRef

346. SungJJ, LauJY, ChingJY, et al.Continuation of low‐dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med2010;152:1. CrossRef

347. AmerM, BeadVR, BathonJ, et al.Use of nonsteroidal anti‐inflammatory drugs in patients with cardiovascular disease: a cautionary tale. Cardiol Rev2010;18:204. CrossRef

348. LanasA, Polo‐TomasM, Casado‐ArroyoR. The aspirin cardiovascular/gastrointestinal risk calculator – a tool to aid clinicians in practice. Aliment Pharmacol Ther2013;37:738. CrossRef

349. DouglasIJ, EvansSJ, HingoraniAD, et al.Clopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designs. BMJ2012;345:e4388. CrossRef

350. BhattDL, CryerBL, ContantCF, et al.Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med2010;363:1909. CrossRef

351. HuntRH, LanasA, StichtenothDO, et al.Myths and facts in the use of anti‐inflammatory drugs. Ann Med2009;41:423. CrossRef

352. Coxib, traditional NTC, BhalaN, et al.Vascular and upper gastrointestinal effects of non‐steroidal anti‐inflammatory drugs: meta‐analyses of individual participant data from randomised trials. Lancet2013;382:769. CrossRef

353. HenryD, LimLL, Garcia RodriguezLA, et al.Variability in risk of gastrointestinal complications with individual non‐steroidal anti‐inflammatory drugs: results of a collaborative meta‐analysis. BMJ1996;312:1563. CrossRef

354. CairnsJA. The coxibs and traditional nonsteroidal anti‐inflammatory drugs: a current perspective on cardiovascular risks. Can J Cardiol2007;23:125. CrossRef

355. KochM, DeziA, FerrarioF, et al.Prevention of nonsteroidal anti‐inflammatory drug‐induced gastrointestinal mucosal injury. A meta‐analysis of randomized controlled clinical trials. Arch Intern Med1996;156:2321. CrossRef

356. de GrootNL, SpiegelBM, van HaalenHG, et al.Gastroprotective strategies in chronic NSAID users: a cost‐effectiveness analysis comparing single‐tablet formulations with individual components. Value Health2013;16:769. CrossRef

357. ElliottRA, HooperL, PayneK, et al.Preventing non‐steroidal anti‐inflammatory drug‐induced gastrointestinal toxicity: are older strategies more cost‐effective in the general population?Rheumatology (Oxford)2006;45:606. CrossRef

358. EkstromP, CarlingL, WetterhusS, et al.Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non‐steroidal anti‐inflammatory drug therapy. A Nordic multicentre study. Scand J Gastroenterol1996;31:753. CrossRef

359. CullenD, BardhanKD, EisnerM, et al.Primary gastroduodenal prophylaxis with omeprazole for non‐steroidal anti‐inflammatory drug users. Aliment Pharmacol Ther1998;12:135. CrossRef

360. LinKJ, Hernandez‐DiazS, Garcia RodriguezLA. Acid suppressants reduce risk of gastrointestinal bleeding in patients on antithrombotic or anti‐inflammatory therapy. Gastroenterology2011;141:71. CrossRef

361. TamuraA, MurakamiK, KadotaJ, et al.Prevalence and independent factors for gastroduodenal ulcers/erosions in asymptomatic patients taking low‐dose aspirin and gastroprotective agents: the OITA‐GF study. QJM2011;104:133. CrossRef

362. ChanFK, ChungSC, SuenBY, et al.Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low‐dose aspirin or naproxen. N Engl J Med2001;344:967. CrossRef

363. LaiKC, LamSK, ChuKM, et al.Lansoprazole for the prevention of recurrences of ulcer complications from long‐term low‐dose aspirin use. N Engl J Med2002;346:2033. CrossRef

364. ChanFK, ChingJY, HungLC, et al.Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med2005;352:238. CrossRef

365. LaiKC, ChuKM, HuiWM, et al.Esomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complications. Clin Gastroenterol Hepatol2006;4:860. CrossRef

366. GrahamDY, AgrawalNM, RothSH. Prevention of NSAID‐induced gastric ulcer with misoprostol: multicentre, double‐blind, placebo‐controlled trial. Lancet1988;2:1277. CrossRef

367. SilversteinFE, GrahamDY, SeniorJR, et al.Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti‐inflammatory drugs. A randomized, double‐blind, placebo‐controlled trial. Ann Intern Med1995;123:241. CrossRef

368. GrahamDY, AgrawalNM, CampbellDR, et al.Ulcer prevention in long‐term users of nonsteroidal anti‐inflammatory drugs: results of a double‐blind, randomized, multicenter, active‐ and placebo‐controlled study of misoprostol vs lansoprazole. Arch Intern Med2002;162:169. CrossRef

369. YilmazS, BayanK, DursunM, et al.Does adding misoprostol to standard intravenous proton pump inhibitor protocol improve the outcome of aspirin/NSAID‐induced upper gastrointestinal bleeding?: a randomized prospective study. Dig Dis Sci2007;52:110. CrossRef

370. LaineL, KivitzAJ, BelloAE, et al.Double‐blind randomized trials of single‐tablet ibuprofen/high‐dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers. Am J Gastroenterol2012;107:379. CrossRef

371. NgFH, WongSY, LamKF, et al.Famotidine is inferior to pantoprazole in preventing recurrence of aspirin‐related peptic ulcers or erosions. Gastroenterology2010;138:82. CrossRef

372. ChanFK, LanasA, ScheimanJ, et al.Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet2010;376:173. CrossRef

373. TargownikLE, MetgeCJ, LeungS, et al.The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti‐inflammatory drugs. Gastroenterology2008;134:937. CrossRef

374. BashinskayaB, NahedBV, RedjalN, et al.Trends in peptic ulcer disease and the identification of Helicobacter pylori as a causative organism: population‐based estimates from the US nationwide inpatient sample. J Glob Infect Dis2011;3:366. CrossRef

375. LauJY, SungJ, HillC, et al.Systematic review of the epidemiology of complicated peptic ulcer disease: incidence, recurrence, risk factors and mortality. Digestion2011;84:102. CrossRef

376. JensenDM, ChengS, KovacsTO, et al.A controlled study of ranitidine for the prevention of recurrent hemorrhage from duodenal ulcer. N Engl J Med1994;330:382. CrossRef

377. GisbertJP, KhorramiS, CarballoF, et al.Meta‐analysis: Helicobacter pylori eradication therapy vs. antisecretory non‐eradication therapy for the prevention of recurrent bleeding from peptic ulcer. Aliment Pharmacol Ther2004;19:617. CrossRef

378. LeontiadisGI, SreedharanA, DorwardS, et al.Systematic reviews of the clinical effectiveness and cost‐effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol Assess2007;11:iii, 1‐164. CrossRef

379. LaineL, McQuaidKR. Endoscopic therapy for bleeding ulcers: an evidence‐based approach based on meta‐analyses of randomized controlled trials. Clin Gastroenterol Hepatol2009;7:33, quiz 1‐2. CrossRef

380. KahiCJ, JensenDM, SungJJ, et al.Endoscopic therapy versus medical therapy for bleeding peptic ulcer with adherent clot: a meta‐analysis. Gastroenterology2005;129:855. CrossRef